Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ: AQST )

2.720 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Aquestive's AQST-109 Compares Favorably To Widely Used EpiPen For Severe Allergic Reaction
Via Benzinga
Why Is Aquestive Therapeutics Stock Up Today?
Aquestive Therapeutics Inc (NASDAQ: AQST) shares are trading higher Tuesday after the company announced results from the EPIPHAST II trial for its AQST-109 epinephrine sublingual film. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers 9 Meters Biopharma (NASDAQ:NMTR) stock moved upwards by 22.8% to $0.25 during Tuesday's pre-market session. The company's market cap stands at $65.8 million. 
Via Benzinga
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy. 
Via Benzinga
Where Aquestive Therapeutics Stands With Analysts
Aquestive Therapeutics (NASDAQ:AQST) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Aquestive Gets FDA Tentative Approval For Libervant In Seizure Clusters Management
The U.S. 
Via Benzinga
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
Aquestive Therapeutics Reveals Favorable Data From Epinephrine Trial For Allergies
Via Benzinga
Why Coupa Software Is Trading Higher By Over 12%; Here Are 24 Stocks Moving Premarket
Gainers Biophytis S.A. (NASDAQ: BPTS) shares rose 41.5% to $1.33 in pre-market trading after the company announced data on Covid treatment. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Metacrine (NASDAQ:MTCR) shares rose 13.8% to $0.54 during Tuesday's after-market session. This security traded at a volume of 3.0 million shares come close, making up 948.6% of its average... 
Via Benzinga
FedEx Faces Price Target Cut By This Analyst; Also Check Out Some Other Major PT Changes
Citigroup cut the price target on FedEx Corporation (NYSE: FDX) from $270 to $225. Citigroup analyst Christian Wetherbee also downgraded the stock from Buy to Neutral. FedEx shares fell 3% to trade at... 
Via Benzinga
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Nuwellis, Inc. (NASDAQ: NUWE) shares jumped 140% to $1.5894 after the company announced new clinical data demonstrating 100% survival at 30 days following the use of ultrafiltration in... 
Via Benzinga
NASDAQ:AQST Investor Notice: Update in Lawsuit Against Aquestive Therapeutics, Inc. Announced
San Diego, CA -- (SBWIRE) -- 08/25/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST). 
Via SBWire
12 Health Care Stocks Moving In Friday's After-Market Session
  
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
Aquestive Therapeutics: Q2 Earnings Insights
Aquestive Therapeutics (NASDAQ:AQST) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Aquestive Therapeutics... 
Via Benzinga
Earnings Preview: Aquestive Therapeutics
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
63 Biggest Movers From Yesterday
Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the... 
Via Benzinga
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Outlook For Aquestive Therapeutics
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ: AQST) AQST-109 for allergic reactions. AQST-109 is an orally delivered epinephrine-based product candidate for the... 
Via Benzinga
Looking Into Aquestive Therapeutics's Return On Capital Employed
Benzinga Pro data, Aquestive Therapeutics (NASDAQ:AQST) reported Q4 sales of $11.08 million. Earnings fell to a loss of $28.95 million, resulting in a 98.87% decrease from last... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.